Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 17,830 matching trials from the live ClinicalTrials.gov search.
Conditions
Erosive Esophagitis
Interventions
BLI5100, PPI Control
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
122
States / cities
Homewood, Alabama • Huntsville, Alabama • Peoria, Arizona + 99 more
Conditions
Arthropathy of Knee
Interventions
Dexamethasone IV, Dexamethasone IV+Oral, Dexamethasone IV+Oral 2 Day
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on the Electrical Activity of the Heart

NCT01537887
Conditions
Healthy Volunteers
Interventions
LY2484595, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Conditions
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Pembrolizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
New York, New York
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions
MEDI-573 (1 of 3 doses), Sorafenib
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada
Conditions
Dyslipidaemias
Interventions
an undetermined dose of GSK1292263, ascending dose of GSK1292263
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Axial Myopia, Refractive Errors
Interventions
Oral Riboflavin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
6 Years to 12 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Thyroid Cancer
Interventions
IMRT, DWI MRI, Doxorubicin, Modified Barium Swallow Impairment Profile (MBSImP)
Radiation · Device · Drug + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Oakland, California • San Leandro, California • Portland, Maine + 2 more
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions
XMT-1001
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 9 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

NCT01772758
Conditions
Cystic Fibrosis
Interventions
BH4 5mg, BH4 20mg, Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
7 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Active, not recruiting Phase 2 Interventional

Surgical Pembro +/- Olaparib w TMZ for rGBM

NCT05463848
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Pembrolizumab, Olaparib, Temozolomide
Drug
Lead sponsor
L. Nicolas Gonzalez Castro, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Active, not recruiting Phase 1 Interventional

Vagal Stimulation in POTS

NCT03124355
Conditions
Postural Tachycardia Syndrome
Interventions
placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Healthy
Interventions
PF-02545920, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut
Conditions
Major Depressive Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Systemic Lupus Erythematosus
Interventions
GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
Interventions
Clofarabine, Total Body Irradiation, Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
Drug · Radiation · Other
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more
Conditions
Hepatitis C, Chronic
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more